@cherisebranchfnp
1 post audited · 2 claims analysed
Science evidence grade
Based on 2 claims across 1 audit
2
Supported
100%
0
Overstated
0%
0
Misleading
0%
0
No Evidence
0%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @cherisebranchfnp claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
100%
2 claims
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
0%
0 claims
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
0%
0 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(1 post)
“Peptide vibes #hormonehealth #functionalmedicine #womenshealth #perimenopause #wellnessbalanceyou #menopausesupport #hormonehealth #texaswellness #hormonebalance #”
Both claims are supported by credible scientific evidence. Peptides' role in anti-aging, longevity, and brain health is established through mechanistic studies (probiotic-derived peptides, bone cytokines, fungal peptides) and early clinical translation (NCT04390646 on GnRH and cognition). GLP-1, GIP, and dual GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) are backed by robust Phase 3 human trial data demonstrating metabolic and cardiovascular benefits, with active clinical development ongoing. The evidence tier ranges from preclinical (C. elegans, in-vitro) to large-scale human RCTs, providing a solid conceptual and clinical foundation for both claims.
Audit another post from @cherisebranchfnp
Paste their social post link to add a new audit